No. You do not shock stable ventricular tachycardia that has a palpable pulse. Synchronized cardioversion is reserved for VT with a pulse that is unstable, meaning it is causing shock, hypotension, ischemia, or altered mentation. Pulseless VT is treated as VF with unsynchronized defibrillation. A stable, perfusing VT is managed with antiarrhythmic drugs or elective cardioversion.

The question is really a decision-tree problem hiding inside four words. The presence of a pulse tells you the heart is still generating cardiac output, which changes the electrical timing problem, the shock energy, and the sedation requirements. The rest of this explainer walks through the mechanism, the thresholds, and the traps that make experienced clinicians pause.

Mechanism: Why Synchronization Changes Everything

A shock works by depolarizing a critical mass of myocardium at once, so the heart's own pacemakers can resume control. In VF, that logic is simple because there is no organized rhythm to track. In VT, the ventricles are already depolarizing in an organized circuit, often at 140 to 250 beats per minute, and every one of those beats is a vulnerable moment if the shock lands on the T wave.

The T wave marks the tail end of repolarization, when some cells are excitable and others are refractory. A shock delivered there can create a new re-entrant circuit and degenerate VT into VF. Synchronized cardioversion solves this by timing the energy to the QRS complex, roughly 30 to 50 milliseconds after the peak, where the myocardium is refractory enough to avoid inducing fibrillation. That timing is the entire reason a pulse changes the plan.

Put plainly: the pulse tells you the rhythm is organized, and organized rhythms should be shocked on the beat, not at random.

Quantified Context: Amplitudes, Energies, and Windows

The practical numbers here are electrical, not statistical, and they vary by device and patient. Synchronized cardioversion for VT typically starts at 100 joules for a monophasic waveform and 50 to 100 joules for biphasic. Defibrillation for pulseless VT or VF typically starts at 120 to 200 joules biphasic or 360 joules monophasic. Those overlapping energies are why misclassifying a rhythm is dangerous but forgiving; the sync mode, not the joule count, is what protects the patient.

The synchronization window itself has limits. Most defibrillators need a QRS amplitude above roughly 0.5 millivolts and a rate below a manufacturer-defined ceiling, often around 300 beats per minute, to lock onto the R wave reliably. Fast polymorphic VT can fool the sync algorithm into tracking the wrong peak, so some devices will not sync at all and will default to unsynchronized delivery. If a monitor displays a sync marker intermittently rather than on every complex, the machine is telling you it cannot see the rhythm clearly.

Heart rate thresholds matter too. VT is conventionally defined as three or more consecutive ventricular beats at more than 100 beats per minute. Rates below that are accelerated idioventricular rhythm, which usually needs no shock at all.

The Stability Thresholds, Reconciled

Multiple frameworks define instability, and they rarely use identical wording. The American Heart Association's advanced cardiovascular life support algorithm describes unstable VT as causing hypotension, altered mental status, shock signs, ischemic chest pain, or acute heart failure. Some hospital protocols add specific numbers, such as a systolic blood pressure below 90 mmHg or a drop of more than 40 mmHg from baseline. Others cite a mean arterial pressure below 65 mmHg, which is the threshold used in sepsis and perfusion literature.

These thresholds do not conflict so much as nest. A systolic pressure of 85 mmHg with clear mentation and warm skin may be tolerated briefly; the same pressure with confusion and cold extremities is unstable. The unifying concept is inadequate perfusion, and the numbers are triggers for looking harder, not binary switches. Treat the patient's perfusion, not the monitor's number. One unit system throughout this article is US customary, and there are no drug doses or energy settings here that should be applied without local protocol.

Edge Cases Where the Rule Bends

Polymorphic VT, including torsades de pointes, is a special case. When it is pulseless, it is defibrillated like VF. When it has a pulse, synchronized cardioversion may be attempted, but the polymorphic waveform can defeat the sync algorithm, and magnesium and correction of the underlying cause often matter more than the shock. This is one of the counterintuitive details: in torsades with a pulse, the electrical therapy is sometimes the least important intervention.

Another edge case is VT in a patient with an implantable cardioverter-defibrillator. The device may deliver its own therapy, including antitachycardia pacing, before anyone touches a manual defibrillator. Antitachycardia pacing works by delivering rapid, low-energy pacing bursts to terminate the re-entrant circuit, and it can break a stable VT without any shock at all. That is a reminder that shock is one tool, not the only tool.

Pacemaker-mediated rhythms and ventricular paced rhythms can also mimic VT and confuse sync detection, since the wide complexes come from a device rather than a re-entrant circuit. A 12-lead electrocardiogram or device interrogation, when time permits, separates the two.

Common Misconceptions and Red-Flag Warnings

Several myths persist in rapid-response training. One is that any wide-complex tachycardia at high rate should be shocked, which conflates pulseless and perfusing rhythms. Another is that sync mode simply delays the shock by a fraction of a second and is otherwise identical, which ignores the induced-fibrillation risk. A third is that a stable VT will inevitably deteriorate, so pre-emptive unsynchronized shock is safer, which skips sedation and can convert a perfusing rhythm into a pulseless one.

Do not press the shock button in sync mode until the sync markers appear on every QRS complex. If the monitor shows no sync markers, do not assume sync failed silently; treat it as an unsynchronized shock decision and confirm the rhythm first. Do not delay cardioversion of unstable VT to obtain a 12-lead ECG or to start an antiarrhythmic infusion. Do not sedate a patient with unstable VT and then wait; sedation is for stable patients or is given immediately before the shock when time allows. Do not shock a stable VT just because the rate looks alarming; rate alone is not instability.

Comparison: Rhythm, Pulse, and Therapy

Rhythm Pulse present Organized QRS Typical therapy Risk of unsynchronized shock
Ventricular fibrillation No No Defibrillation Intended therapy
Pulseless VT No Yes Defibrillation Intended therapy
Unstable VT Yes Yes Synchronized cardioversion Can induce VF
Stable VT Yes Yes Antiarrhythmic or elective cardioversion Unnecessary and risky
Polymorphic VT with pulse Yes Variable Sync attempt or drug therapy Sync may fail
Accelerated idioventricular rhythm Usually yes Yes Observation Unnecessary

Timeline: What Happens During a VT Event

Time (approx.) Event Clinical implication
0 seconds VT onset, pulse may or may not be present Check pulse and perfusion first
Seconds to minutes Blood pressure falls as rate rises and filling time shortens Symptoms reveal stability
Within minutes Sync algorithm locks onto QRS if amplitude allows Confirm markers before shock
Shock moment Synchronized energy delivered QRS-timed to avoid T-wave
Seconds after shock Rhythm converts to sinus or degenerates Reassess pulse and monitor
Minutes after Recurrence possible if substrate uncorrected Treat ischemia and electrolytes

The time course explains why the first sixty seconds are the most consequential. Pulseless VT collapses output immediately, while perfusing VT may hold pressure for minutes or may not. That variability is precisely why the algorithm asks for a pulse check and a perfusion assessment before any energy is delivered.

Practical Actions and Limitations

The sequence for a patient with wide-complex tachycardia is straightforward. Confirm the rhythm and rate, check for a pulse, and assess perfusion using blood pressure, mentation, skin, and chest pain. If pulseless, defibrillate immediately per protocol. If pulseless VT is present, treat it exactly like VF. If a pulse is present and instability is evident, perform synchronized cardioversion with sedation when feasible. If a pulse is present and the patient is stable, pursue antiarrhythmic therapy, correct electrolytes, and obtain cardiology input.

The limitations deserve equal weight. Sync detection depends on signal quality and amplitude, so a poor lead placement can prevent it. Polymorphic rhythms may not sync reliably. Sedation carries its own hemodynamic risk in a borderline patient. And none of this addresses the underlying cause, which is usually ischemia, structural heart disease, or an electrolyte abnormality. Defibrillation converts the rhythm; it does not treat the disease.

The evidence base for these recommendations comes primarily from consensus resuscitation guidelines rather than randomized trials, since randomizing unstable VT to shock versus no shock is not ethically feasible. That means the thresholds are expert-derived and should be applied with clinical judgment, not as rigid cutoffs (American Heart Association, Advanced Cardiovascular Life Support Provider Manual).

The final point is the one most worth remembering. The question of whether to shock V-tach with a pulse is answered by perfusion, not by the rhythm strip alone, and the synchronized mode exists because timing a shock to the QRS is what keeps an organized rhythm from becoming a disorganized one.